OncoMatch/Clinical Trials/NCT06876649
A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
Is NCT06876649 recruiting? Yes, currently enrolling (May 2026). This Phase 4 trial studies Pirtobrutinib for chronic lymphocytic leukemia.
Treatment: Pirtobrutinib — The master protocol study J2N-MC-JZNY provides a framework to enable the evaluation of the long-term safety and efficacy of pirtobrutinib after completion of clinical studies evaluating pirtobrutinib. The clinical studies that will feed into this master protocol are referred to as originator studies. The master protocol will govern individual study-specific appendices (ISAs) that will represent participants from the individual, completed originator studies. These participants will have the opportunity to enter this study and continue to receive treatment or continue follow-up visits. Overall, the master protocol and the individual ISAs, when combined, define the investigations for this study.
Check if I qualifyExtracted eligibility criteria
Cancer type
Chronic Lymphocytic Leukemia
Non-Hodgkin Lymphoma
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Cancer Specialists, LLC · Jacksonville, Florida
- Sylvester Comprehensive Cancer Center · Miami, Florida
- Florida Cancer Specialists · Sarasota, Florida
- The Emory Clinic · Atlanta, Georgia
- Northwestern University · Chicago, Illinois
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify